 |
65 Diseases |  |
14 Trials |
|
14 Trials |  |
1875 News |  |
| «12...567891011121314151617 |
- rivastigmine / Generic mfg.
Trial completion: RIVA-1: A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=15, Completed, Sponsor: Tel-Aviv Sourasky Medical Center
Not yet recruiting --> Completed
- |||| rivastigmine / Generic mfg.
Trial completion: Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease (clinicaltrials.gov) - Feb 22, 2014
P4, N=80, Completed, Sponsor: Novartis
Not yet recruiting --> Completed No longer recruiting --> Completed
- ||||||| rivastigmine / Generic mfg.
Trial completion: Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia (clinicaltrials.gov) - Feb 22, 2014
P3, N=708, Completed, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed No longer recruiting --> Completed
- rivastigmine / Generic mfg.
Enrollment closed: DS-Riv: Rivastigmine Study in Adolescents With Down Syndrome (clinicaltrials.gov) - Jan 15, 2014
P1/2, N=40, Active, not recruiting, Sponsor: Duke University
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
New P3 trial: Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease (clinicaltrials.gov) - Jan 12, 2014
P3, N=50, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
- donepezil / Generic mfg.
Enrollment open: Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly (clinicaltrials.gov) - Jan 9, 2014
P4, N=170, Recruiting, Sponsor: New York State Psychiatric Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| MK-7622 / Merck (MSD)
Enrollment open: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Nov 4, 2013
P2a, N=830, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| MK-7622 / Merck (MSD)
Enrollment change: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Sep 29, 2013
P2a, N=830, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=640 --> 830
- | donepezil / Generic mfg.
New P4 trial: Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly (clinicaltrials.gov) - Sep 24, 2013
P4, N=170, Recruiting, Sponsor: New York State Psychiatric Institute
- ||||| rivastigmine / Generic mfg.
New P4 trial: INSTINCT: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (clinicaltrials.gov) - Sep 22, 2013
P4, N=186, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| MK-7622 / Merck (MSD)
Trial initiation date: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Jul 8, 2013
P2a, N=830, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=640 --> 830 Initiation date: May 2013 --> Oct 2013
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, P3 data: Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Jun 5, 2013
P3, N=396, Recruiting, Sponsor: AB Science
- | rivastigmine / Generic mfg.
New P4 trial: CHEVAL: Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease (clinicaltrials.gov) - May 15, 2013
P4, N=168, Not yet recruiting, Sponsor: VU University Medical Center
- ||||| MK-7622 / Merck (MSD)
New P2a trial: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - May 9, 2013
P2a, N=830, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| rivastigmine transdermal / Generic mfg., rivastigmine / Generic mfg.
Trial initiation date: Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia (clinicaltrials.gov) - Jan 9, 2013
P4, N=127, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: May 2013 --> Oct 2013 Initiation date: Apr 2012 --> Aug 2012
- |||| rivastigmine transdermal / Generic mfg., rivastigmine / Generic mfg.
Enrollment open: Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia (clinicaltrials.gov) - Jan 9, 2013
P4, N=127, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Apr 2012 --> Aug 2012 Not yet recruiting --> Recruiting
- rivastigmine / Generic mfg.
Enrollment change: Efficacy of Rivastigmine in Patients With Down Syndrome (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=14, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting N=20 --> 14
- rivastigmine / Generic mfg.
Trial completion: Efficacy of Rivastigmine in Patients With Down Syndrome (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=14, Completed, Sponsor: National Taiwan University Hospital
N=20 --> 14 Recruiting --> Completed
- | rivastigmine / Generic mfg.
Biomarker, Trial completion: Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease (clinicaltrials.gov) - Oct 16, 2012
P4, N=12, Completed, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Completed Active, not recruiting --> Completed
- | rivastigmine / Generic mfg.
New P2 trial: Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine (clinicaltrials.gov) - Sep 26, 2012
P2, N=125, Completed, Sponsor: Shaheed Beheshti Medical University
- |||| sembragiline (RO4602522) / Roche, Evotec
Enrollment open: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - Sep 13, 2012
P2, N=495, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| sembragiline (RO4602522) / Roche, Evotec
New P2 trial: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - Aug 30, 2012
P2, N=495, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| rivastigmine transdermal / Generic mfg., rivastigmine / Generic mfg.
New P4 trial: Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia (clinicaltrials.gov) - Apr 23, 2012
P4, N=127, Recruiting, Sponsor: Novartis Pharmaceuticals
- methamphetamine / Generic mfg., rivastigmine / Generic mfg.
Trial completion: Rivastigmine as a Treatment for Methamphetamine Dependence (clinicaltrials.gov) - Feb 19, 2012
P1, N=17, Completed, Sponsor: Baylor College of Medicine
Not yet recruiting --> Recruiting Recruiting --> Completed
- rivastigmine / Generic mfg.
Trial completion: ADFRMI: Rivastigmine in Mild Alzheimer's Disease, FMRI Study (clinicaltrials.gov) - Oct 26, 2011
P=N/A, N=20, Completed, Sponsor: Kuopio University Hospital
Recruiting --> Completed Active, not recruiting --> Completed